Ausgabe 3/2017
Inhalt (15 Artikel)
Development of chemotherapeutics in oncology: is there anything new?
- editorial
Holger Rumpold, Thomas Winder
An Austrian view of the 2017 consensus for the treatment of early breast cancer
- editorial
Guenther G. Steger
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
- Open Access
- short review
Markus Kieler, Matthias Unseld, Daniela Bianconi, Gerald W. Prager
Renal insufficiency in patients with multiple myeloma
- review
Boris Bozic, Sophie Hölbling, Vanessa Völkel, Christian Sebesta
Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
- case report
Branka Petricevic, Wolfgang Hilbe, Niklas Zojer
Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia
- review
Maria Kavianpour, Neda Ketabchi, Najmaldin Saki
Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
- case report
Sonja Burgstaller, Josef Thaler
Highlights from the 2017 St. Gallen Breast Cancer Consensus
- comment
Georg Pfeiler, Rupert Bartsch, Florian Fitzal
New diagnostic tools for breast cancer
- Open Access
- short review
Pascal A. T. Baltzer, Panagiotis Kapetas, Maria Adele Marino, Paola Clauser
